Gland Pharma Limited — Investor Meet, 11-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Gland Pharma reported a strong Q1 FY26, with consolidated revenue up 7% to INR 1,505.6 Cr and EBITDA surging 39% to INR 367.8 Cr, achieving a 24% margin. Net profit rose 50% to INR 215.5 Cr. Crucially, Cenexi achieved EBITDA breakeven, driven by volume, efficiency, and price hikes, with an order book of EUR 85-90M. Gland’s base business EBITDA margin hit 35%. The company is expanding its pen/cartridge capacity from 40M to 140M units by March/April 2026, targeting 20M units supply in FY27, capitalizing on GLP-1 opportunities. Nine new products launched in the US, contributing to anticipated mid-teen growth for FY26. Strategic focus includes RTU bags ($760M market), complex injectables, and RoW expansion. Management expresses confidence in continued performance improvement.